Pancreatic Cancer Therapeutics And Diagnostics Market Size (2024 - 2029)

Pancreatic Cancer Therapeutics and Diagnostics Market Analysis

The Pancreatic Cancer Therapeutics And Diagnostics Market size is estimated at USD 4.56 billion in 2024, and is expected to reach USD 6.55 billion by 2029, growing at a CAGR of 7.52% during the forecast period (2024-2029).

Pancreatic cancer therapeutics and diagnostics involve medical procedures for diagnosing pancreatic cancer and subsequent treatment. Factors such as the increasing prevalence and incidence of pancreatic cancer and advancements in molecular biology, drug development, and diagnostic technology play a major part in market growth. With the increase in research and development initiatives, favorable reimbursement scenarios, and the launch of novel products, the market is expected to grow significantly during the forecast period. For instance, according to the Australian Pancreatic Cancer Foundation Statistics published in 2023, pancreatic cancer was diagnosed in 4,506 patients in 2023. Pancreatic cancer was the eighth most prevalent disease diagnosed in Australia in 2023. Thus, the growing burden of pancreatic cancer is expected to boost the demand for effective diagnosis and treatment, which is likely to propel the growth of the market during the forecast period. Rising research and development activities for pancreatic cancer medication, as well as a large product pipeline, may increase product approval by regulatory authorities, increasing the accessibility and availability of a greater number of drugs to treat pancreatic cancer and contributing to market growth. For instance, in February 2023, updated results of the fully enrolled cohort of the phase 2 QUILT 88 study (NCT03563144) showed a doubling of survival in third-line patients with metastatic pancreatic cancer when treated with the novel combination immunotherapy protocol of low-dose chemoradiation, N-803, and PDL1 t-haNK therapy. Also, in April 2023, Cantargia reported new findings from the phase I/IIa clinical trial CANFOUR, designed to evaluate nadunolimab in combination with chemotherapy for treating pancreatic cancer. Patients with high tumor levels of IL1RAP benefit from nadunolimab treatment. Hence, promising clinical trial studies lead to product approvals, which are expected to drive the market during the forecast period. Thus, all aforementioned factors, such as the increasing prevalence of pancreatic cancer and rising research and development activities, are expected to boost the market growth during the forecast period. However, the high cost of diagnosis and treatment may restrain the growth of the pancreatic cancer therapeutics and diagnostics market during the forecast period.

Pancreatic Cancer Therapeutics and Diagnostics Industry Segmentation

As per the scope, pancreatic cancer occurs when there is an uncontrollable growth of cells in the pancreas. Pancreatic cancer is categorized as exocrine and endocrine based on the cells affected by cancer. The pancreatic cancer therapeutics and diagnostics market is segmented by type, end user, and geography. By type, the market is segmented into treatment (targeted therapies, chemotherapy, surgery, and other treatments) and diagnostics (imaging, biopsy, endoscopic ultrasound, and other diagnostics). By end user, the market is segmented into hospitals, clinics, and other end users. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.